Key Points
- Insider selling: EVP Alaleh Nouri sold 5,363 shares on March 19 at $25.96 (≈$139,223), and in total sold 15,802 shares in recent March transactions (Mar 6, 10, 17, 19) for roughly $394,300, reducing her stake by 4.84% to 105,354 shares.
- Company context: PROCEPT (PRCT) trades near $25.73 with a $1.45B market cap, recently missed estimates (Q EPS -$0.53 vs -$0.32; revenue $76.38M vs $93.7M) and carries a consensus analyst rating of Hold with a $40.82 price target.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Get Free Report) EVP Kevin Waters sold 706 shares of the business's stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $28.15, for a total value of $19,873.90. Following the completion of the transaction, the executive vice president directly owned 151,558 shares of the company's stock, valued at $4,266,357.70. The trade was a 0.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Kevin Waters also recently made the following trade(s):
- On Friday, March 6th, Kevin Waters sold 6,721 shares of PROCEPT BioRobotics stock. The stock was sold at an average price of $23.70, for a total transaction of $159,287.70.
PROCEPT BioRobotics Stock Performance
Shares of PRCT traded up $0.15 during trading hours on Friday, hitting $25.83. The stock had a trading volume of 118,148 shares, compared to its average volume of 1,651,929. The firm has a 50-day moving average price of $28.13 and a 200 day moving average price of $32.17. PROCEPT BioRobotics Corporation has a fifty-two week low of $19.35 and a fifty-two week high of $66.85. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -15.09 and a beta of 1.02. The company has a debt-to-equity ratio of 0.14, a quick ratio of 5.77 and a current ratio of 6.85.
PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.21). The firm had revenue of $76.38 million for the quarter, compared to analyst estimates of $93.70 million. PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 25.13%. The firm's quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.35) EPS. As a group, research analysts anticipate that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current year.
Institutional Trading of PROCEPT BioRobotics
Large investors have recently made changes to their positions in the company. DNB Asset Management AS purchased a new stake in shares of PROCEPT BioRobotics during the third quarter worth $1,132,000. Chicago Capital LLC lifted its stake in shares of PROCEPT BioRobotics by 175.7% in the third quarter. Chicago Capital LLC now owns 1,568,845 shares of the company's stock worth $55,992,000 after buying an additional 999,873 shares in the last quarter. C WorldWide Group Holding A S purchased a new position in shares of PROCEPT BioRobotics in the third quarter worth about $5,354,000. Granite Investment Partners LLC acquired a new position in PROCEPT BioRobotics during the second quarter worth about $8,159,000. Finally, Peregrine Capital Management LLC purchased a new stake in PROCEPT BioRobotics during the 3rd quarter valued at about $6,718,000. 89.46% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities analysts recently weighed in on PRCT shares. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of PROCEPT BioRobotics in a report on Thursday, January 22nd. Robert W. Baird started coverage on PROCEPT BioRobotics in a research report on Friday, March 6th. They issued a "neutral" rating and a $30.00 price objective for the company. Leerink Partners reduced their target price on PROCEPT BioRobotics from $55.00 to $30.00 and set an "outperform" rating for the company in a research note on Thursday, February 26th. Morgan Stanley dropped their price target on shares of PROCEPT BioRobotics from $56.00 to $51.00 and set an "overweight" rating on the stock in a research note on Tuesday, December 2nd. Finally, Wall Street Zen lowered shares of PROCEPT BioRobotics from a "hold" rating to a "sell" rating in a report on Saturday, February 28th. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $40.82.
Read Our Latest Stock Report on PRCT
PROCEPT BioRobotics Company Profile
(
Get Free Report)
PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company's technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.
The company's flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
